Is I-Mab ADR (IMAB) Stock About to Get Hot Friday?

Overall market sentiment has been high on I-Mab ADR (IMAB) stock lately. IMAB receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

I-Mab ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IMAB!

See Full IMAB Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IMAB Stock Today?

I-Mab ADR (IMAB) stock has gained 15.81% while the S&P 500 is lower by -0.36% as of 11:42 AM on Friday, Jan 13. IMAB has gained $1.01 from the previous closing price of $6.39 on volume of 1,315,873 shares. Over the past year the S&P 500 has fallen -16.02% while IMAB is lower by -81.73%. IMAB lost -$4.27 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for I-Mab ADR click here.

More About I-Mab ADR

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature. Click Here to get the full Stock Report for I-Mab ADR stock.